Investment of Retained Earnings in In-House Product Development and Production
First written in FY2016. 5 of 9 entries say "Restated". Latest entry: FY2026.
4 other companies' latest entry also says "Raised".
- FY2026RaisedAnnual report
「We plan to accelerate growth investments going forward by establishing an M&A investment budget of ¥5 billion to ¥10 billion, continuing to invest in overseas startups to acquire future product pipelines, and investing to expand global manufacturing capacity. In addition, we will manage our own research and development investment using approximately 8% to 10% of revenue from proprietary products as a guideline, with the aim of maximizing investment efficiency.」
The Company specified target levels for the uses of retained earnings and operating cash flow, including an M&A budget of ¥5 billion to ¥10 billion, investment in overseas startups, expansion of global manufacturing capacity, and research and development expenses of 8% to 10%. - FY2025AdvancedAnnual report
「Maintain approximately ¥10 billion in cash on hand to ensure financial security; allocate funds based on growth opportunities and financial conditions; make growth investments, including capacity expansion associated with research and development and global initiatives」
The Company specified a policy of maintaining approximately ¥10 billion in retained earnings and cash on hand for financial security, then allocating funds to equipment upgrades, research and development, global initiatives, dividends, and treasury share repurchases. - FY2023RestatedAnnual report
「We have invested in loans and investments to business partners to secure marketing rights for products and strengthen relationships with suppliers, as well as actively investing in factories and equipment to support research and development of proprietary products and strengthen production capacity. Going forward, we will continue to make active investments necessary for future growth, including securing a product pipeline and developing and manufacturing proprietary products, while placing greater emphasis than before on returns on investment.」
The Company has reaffirmed its policy of investing in the product pipeline and the research, development and production capacity of proprietary products, with greater emphasis on returns on investment. - FY2022RestatedAnnual report
「We intend to achieve sustained growth in corporate value by investing retained earnings in expanding our proprietary products through research and development and strengthening production capabilities, a core systems renewal project, and treatment areas outside the cardiovascular field, including gastroenterology.」
The Company reaffirmed its policy of investing retained earnings in research and development and production of proprietary products, core systems renewal, and areas including gastroenterology. - FY2020RaisedAnnual report
「We intend to invest retained earnings in the development and production of proprietary products that leverage our strengths, the development of treatment areas outside the cardiovascular field, M&A aimed at overseas expansion, and the acquisition of marketing rights to secure a product pipeline, which are among our medium-term challenges, thereby achieving sustained growth in corporate value.」
The planned uses of retained earnings were explicitly expanded beyond the development and production of proprietary products to include the development of treatment areas outside the cardiovascular field, M&A for overseas expansion, and the acquisition of marketing rights. - FY2019RestatedAnnual report
「We intend to invest retained earnings in the development and production of proprietary manufactured products that leverage our strengths, with the aim of improving business performance.」
The Company has reiterated its policy of reinvesting retained earnings in the development and production of proprietary products. - FY2018RestatedAnnual report
「We intend to invest retained earnings in the development and production of proprietary manufactured products that leverage our strengths, with the aim of improving business performance.」
The Company has reiterated its policy of reinvesting retained earnings in the development and production of proprietary products. - FY2017RestatedAnnual report
「We intend to invest retained earnings in the development and production of proprietary manufactured products that leverage our strengths, with the aim of improving business performance.」
The Company has reiterated its policy of reinvesting retained earnings in the development and production of proprietary products. - FY2016First statedAnnual report
「We intend to invest retained earnings in the development and production of proprietary manufactured products that leverage our strengths, with the aim of improving business performance.」
Alongside shareholder returns, the Company's capital allocation policy includes reinvesting in the development and production of proprietary manufactured products.